Introduction
Type Ⅲ hyperlipidemia (HL) is a rare familial disorder characterized by a combined elevation in serum total cholesterol (TC) and triglycerides (TG), based on the marked accumulation of remnant lipoproteins, including chylomicron (CM) and VLDL remnants 1) . Many recent studies have proved that oxidized LDL and remnant lipoproteins have atherogenic features 2, 3) and a strong correlation with the morbidity of coronary heart disease (CHD) [4] [5] [6] [7] ; therefore, type Ⅲ HL should be diagnosed and treated as soon as possible.
B-48 to TG (B-48/TG) ratio was significantly higher only in patients with type Ⅲ HL than in those with other types of HL, none of whom had received any lipid-lowering interventions 17) . It has been suggested that a high apo B-48/TG ratio is related to the accumulation of small CM remnants, which contain one molecule of apo B-48 and smaller amounts of TG than those of the larger CMs or CM remnants. Small CM remnants may be accumulated after therapy because of a genetic disorder of apoE, and a high apoB-48/TG ratio might be useful for detecting type Ⅲ HL even after the initiation of lipid-lowering interventions.
Thus, the aim of the present study was to evaluate whether the apo B-48/TG ratio is useful for detecting type Ⅲ HL even after the initiation of lipid-lowering interventions.
Subjects and Methods

Subjects and Patients
Subjects with NL and patients with HL were identified from candidates registered in the central registration database for evaluating the clinical usefulness of apo B-48 in patients with dyslipidemia, diabetes mellitus, MetS, and CHD. These candidates consisted of cardiovascular medicine outpatients at Osaka University Hospital (n = 151) and another university hospital in Japan (n = 65). Fasting TC and TG levels at the time of diagnosis, before any lipid-lowering interventions for dyslipidemia were administered, were examined for all subjects (n = 216). HL was diagnosed using criteria based on the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases among Japanese individuals 24) . First, 25 subjects were considered to have NL as they had low TC and TG levels (TC ＜220 mg/dL and TG ＜150 mg/dL). The remaining 192 subjects were diagnosed with HL as they had high TC and TG levels (TC ≥ 220 mg/dL and/or TG ≥ 150 mg/dL) and had not received any lipid-lowering agents. The HL phenotype was determined based on the criteria proposed by the Research Committee for Primary Hyperlipidemia of the Ministry of Health and Welfare of Japan 24) . The diagnosis of type Ⅲ HL (n = 12) with the apo E2/2 phenotype was performed based on the standard criteria previously reported 25) . All patients with HL were already undergoing treatment with oral agents for hyperlipidemia, including statins, fibrates, probucol, nicotinic acid, and anionexchange resins. This study was approved by the Ethics Committee of Osaka University Hospital and the other university hospital; informed consent was obtained from all participants in this study.
Type Ⅲ HL can be definitively diagnosed by phenotyping (genotyping) apo E (mainly apo E2/E2) using Western blotting or isoelectric focusing, and by demonstrating the presence of a broad β pattern (consisting of β-VLDL, IDL or VLDL remnants) on agarose gel electrophoresis or polyacrylamide gel disc electrophoresis (PAGE) [8] [9] [10] [11] ; however, these analyses are time-consuming and inconvenient for routine clinical use. Moreover, in clinical settings, HL patients are promptly treated with diet and exercise therapy as well as lipid-lowering agents without diagnosing the underlying cause.
Five groups of investigators have identified clinical indices for screening type Ⅲ HL. The apo E/apo B ratio was significantly greater in patients with type Ⅲ HL than in those with other types of HL 12) . The apo B/TC ratio was significantly lower in patients with dysbetalipoproteinemia whose apo E genotype was E2/E2 than in those with mixed HL 13) . A simple algorithm was developed for the diagnosis of type Ⅲ HL on the basis of a TC/apo B ratio of ＞6.2 and a TG/ apo B ratio of ＜10.0, which were not detected in patients with other types of HL 14) . The non-HDL-C/ apo B ratio was significantly greater in patients with type Ⅲ HL and an apo E genotype of E2/E2 than in those with combined HL other than type Ⅲ HL or hypothyroidism 15) . In Japanese patients with type Ⅲ HL (apo E2/2 phenotype), the apo E/C-Ⅲ index was considerably higher than in patients with other types of HL 16) . As these studies were well designed and had high sensitivity and specificity for screening untreated type Ⅲ HL, these clinical criteria might be distorted and their specificity and sensitivity might decrease after lipid-lowering intervention. Drug withdrawal for the diagnosis of type Ⅲ HL may increase the risk of cardiovascular events; therefore, practical and simple criteria for screening type Ⅲ HL after lipid-lowering intervention must be established.
A novel sandwich enzyme-linked immunosorbent assay (ELISA) 17) and chemiluminescent enzyme immunoassay (CLEIA) system 18) to measure serum apo B-48 were developed. Fasting apo B-48 levels are correlated with postprandial TG increase 19) and are significantly higher in patients with accumulated CM and CM remnants 17) and metabolic syndrome (MetS) 20) . High fasting apo B-48 levels are correlated with premature carotid artery stenosis 21, 22) , and postprandial increases in TG and apo B-48 are correlated with CHD 23) . Emerging evidence has suggested that CM remnants are responsible for the initiation and development of atherosclerotic plaques in vitro and in vivo 2) . In our previous study, we observed high fasting serum TG and apo B-48 in patients with type Ⅲ HL and the apo Inc., Tokyo, Japan) 18) . A broad β pattern of serum lipoproteins was determined by PAGE, and the presence of the apo E phenotype was determined by isoelectric focusing gel electrophoresis (JOKOH Co., Tokyo, Japan) 26) . All samples were treated in accordance with the Helsinki Declaration 27) . Non-HDL-C levels were calculated by subtracting HDL-C values from TC values. Clinical indices for screening type Ⅲ HL (apo E/apo B ratio, apo B/ TC ratio, TC/apo B ratio, TG/apo B ratio, non-HDL-C/apo B ratio, and apo E/C-Ⅲ ratio) were calculated [12] [13] [14] [15] [16] in addition to the apo B-48/TG ratio 17) .
Statistical Analysis
Biochemical parameters concerning lipid and lipoprotein profiles without apo B-48 were normally
Measurements
In all subjects, height and weight were measured, body mass index (BMI) was calculated, and blood pressure was measured in a sitting position in the morning. Blood samples were collected in the morning after an overnight fast. Sera were separated immediately by low-speed centrifugation (3,000×g) for 10 min at 4 ℃ and stored at −80 ℃ until used. Serum TC and TG were determined by an enzymatic method; serum LDL-C and HDL-C levels by a direct method using Cholestest N HDL (Sekisui Medical Co Ltd, Tokyo, Japan) and Cholestest LDL (Sekisui Medical Co Ltd, Tokyo, Japan); and serum apo B, apo E, and apo C-Ⅲ levels by an immunoturbidity method (Sekisui Medical Co Ltd). Serum apo B-48 levels were determined using our own CLEIA system (Fuji Rebio cance was declared if the one-sided p value was ＜0.05. Receiver-operating characteristic (ROC) curves were used to examine the value of the apo B-48/TG ratio useful for categorizing subjects on the basis of the presence of type Ⅲ HL. Data were analyzed by linear discriminant analysis, and the error rate for subjects with NL and subjects with other types of HL was evaluated relative to patients with type Ⅲ HL. Statistical analyses were performed using JMP 9 software (SAS Institute, Cary, NC).
Results
Clinical Profiles of Patients with HL after AntiHyperlipidemic Intervention
The clinical profiles and biochemical markers of lipid and lipoprotein metabolism were compared among subjects with NL and patients with type Ⅰ, Ⅱa, Ⅱb, Ⅲ, Ⅳ, and Ⅴ HL ( Table 1) . Patients with HL were already receiving treatment with lipid-lowering drugs. distributed variables, and apo B-48 levels were nonparametric variables 17, 21) ; these levels are expressed as the mean±SD. The overall difference in biochemical parameters, apoB-48 and the apoB-48/TG ratio was compared between subjects with NL and patients with any type of HL, one-way ANOVA with Dunnett's multiple comparison tests were used for the difference in biochemical parameters and the Kruskal-Wallis and Steel's tests were used for that in apo B-48 and the apo B-48/TG ratio. Moreover, differences in the apo B-48/ TG ratio between patients with type Ⅲ HL and subjects with NL as well as patients with other types of HL were analyzed by Wilcoxon's rank sum test. Multiple comparisons in clinical indices for screening type Ⅲ HL [12] [13] [14] [15] [16] Table 2 ; these patients had already been treated with fibrates (fenofibrate or bezafibrate) and statins. TC levels were significantly higher among patients with type Ⅱa and Ⅴ HL than among subjects with NL after lipid-lowering treatments; however, there was no significant difference in LDL-C levels between these groups. TG levels were much higher among patients with type Ⅰ and Ⅴ HL than in subjects with NL, but not among patients with type Ⅲ HL (Table 1, 2 and Fig. 1) . Apo B levels were significantly higher among patients with type Ⅴ HL than among subjects with NL, but not among patients with type Ⅱa or Ⅱb HL. Apo E levels were significantly higher among patients with type Ⅰ, Ⅲ, and Ⅴ HL, and apo C-Ⅲ levels were significantly higher among patients with type Ⅰ and Ⅴ HL than subjects with NL ( Table 1) .
ApoB-48 Levels and Apo B-48/TG Ratios
As shown in Table 1 and Fig. 1 , there was no significant difference in TG levels between patients with type Ⅲ HL and subjects with NL; however, apo B-48 levels among patients with type Ⅰ, Ⅲ, and Ⅴ HL were significantly higher than among subjects with NL (p＜0.001) (Table 1 and Fig. 1) . The apo B-48/TG ratio was also significantly higher among patients with type Ⅲ HL than among subjects with NL (p＜0.001, assessed by Steel's multiple comparisons test) and patients with other types of HL (p＜0.001, assessed by Wilcoxon's rank sum test). When discriminating patients with type Ⅲ HL from patients with other types of HL, the apo B48/TG ratio yielded an AUC-ROC value of 0.895 (Fig. 2) Fasting TG levels (A), apo B-48 levels (B) and apo B-48/TG ratio (C) were determined for 25 subjects with NL, and type Ⅰ (n = 6), type Ⅱa (n= 62), type Ⅱb (n= 66), type Ⅲ (n= 12), type Ⅳ (n= 22), and type Ⅴ (n = 23) HL patients. Data are expressed as a scatter plot using the mean±SD. . Nutritional or pharmacological interventions are administrated to these patients as soon as possible without investigating the etiology of dyslipidemia, so the assessment of HL type in patients with dyslipidemia on the basis of their biochemical data, such as TC and TG levels, is very difficult. In this study, we assessed a simple marker for screening type Ⅲ HL,the apoB-48/TG ratio, which is suitable for use even after initiation of lipid-lowering interventions.
Clinical Profiles of Type Ⅲ HL after Initiation of Lipid-Lowering Interventions
Appropriate intervention with lipid-lowering drugs reduces levels of lipids and apolipoproteins to within normal limits in some patients with HL ( Table 1) . TG and apo B-48 levels were decreased after administration of lipid-lowering drugs to patients with type Ⅰ, Ⅲ, Ⅳ, and Ⅴ HL compared with those before administration of these drugs, but not in patients with type Ⅱa and Ⅱb HL (17 and Table 1 ). Fibrate administration decreased TG levels in patients with type Ⅲ HL to the levels observed in subjects with NL, but it did not achieve a sufficient TG decrease in patients with type Ⅰ and Ⅴ HL (Fig. 1A) . On the other hand, apo B-48 levels remained significantly high in patients with type Ⅲ HL as well as type Ⅰ and Ⅴ HL after the administration of fibrates. We suspected that these differences in lipid-lowering effects between type Ⅰ, Ⅲ, and Ⅴ HL may be due to increased deterioration of LPL activity by fibrates or nicotinic acids. Since fibrates enhance LPL-mediated catabolism of VLDL-TG and CM-TG, the TG content of remnant lipoproteins might have decreased and their particle sizes diminished. In patients with type Ⅲ HL, increased type Ⅲ HL even after lipid-lowering interventions. The cut-off value of the apo B48/TG ratio was identified as 0.110; linear discriminant analysis revealed a 2.8% error rate for all types of HL and NL vs. type Ⅲ HL.
Apo B48/TG Ratio and Other Proposed Clinical Indices for Screening of Type Ⅲ HL
Many researchers have proposed clinical indices for screening type Ⅲ HL [12] [13] [14] [15] [16] ; we evaluated whether these clinical indices and the apo B-48/TG ratio remained useful for screening type Ⅲ HL after the initiation of lipid-lowering interventions (Table 3) . Analyses were performed with Dunnett's or Steel's multiple comparison tests; statistical significance of differences was observed between patients with type Ⅲ HL and those with other types of HL when we adopted the apo E/apo B, apo B/TC, TC/apo B, apo E/apo C-Ⅲ, and apo B-48/TG ratios. However, when the apo E/apo B, and TC/apo B ratios were adopted, a statistically significant difference was also observed between patients with type Ⅰ HL and those with other types of HL. When the apo B/TC ratio was adopted, a statistically significant difference was also observed between patients with type Ⅰ, Ⅱa, Ⅲ, and Ⅳ HL and those with other types of HL. Only when the apo B-48/TG ratio was adopted was a statistically significant difference observed only between patients with type Ⅲ HL and those with other types of HL.
Discussion
The accumulation of "atherogenic" remnants in patients with type Ⅲ HL is strongly correlated with the development of atherosclerotic cardiovascular dis- 12) apoB/TC 13) TC/apoB 14) TG/apoB 14) non-HDL-C/apoB 15) apoE/apoCⅢ 16) apoB48 genetically impaired in patients with type Ⅰ HL, and fibrates might not be able to decrease TG and apoB-48 levels. As a result, high apo B-48 levels and low TG levels were observed in patients with type Ⅲ HL after the administration of fibrates.
LPL activity may decrease VLDL-TG and CM-TG but not the number of VLDL and CM remnants, because liver uptake of them is impaired due to genetic apo E abnormality. Apo E and apo CⅢ were significantly higher in patients with type Ⅰ, Ⅲ, and Ⅴ HL (Table 1) , which might also be due to impaired liver uptake of remnant lipoproteins. LPL activity is The apo E/apo B (A), apo B/TC (B), TC/apo B (C), TG/apo B (D), non HDL-C/apo B (E) and apo E/apo C-Ⅲ ratios (F) were determined in 25 subjects with NL, and type Ⅰ (n = 6), type Ⅱa (n = 62), type Ⅱb (n = 66), type Ⅲ (n = 12), type Ⅳ (n = 22), and type Ⅴ (n = 23) HL patients. Data are expressed as a scatter plot using the mean±SD.
were 3-fold higher but apo C-Ⅲ levels were 2-fold higher than in NL subjects, which might be due to the marked accumulation of remnant lipoproteins associated with apo E 16) . After lipid-lowering intervention, high apo E levels were still observed in patients with type Ⅰ, Ⅲ, and Ⅴ HL, and high apo C-Ⅲ levels were observed in patients with type Ⅰ and Ⅴ HL (Table 1) ; however, high apo E/apo C-Ⅲ ratios were observed in patients with not only type Ⅲ but also type Ⅱb, Ⅳ, and Ⅴ HL (Table 3 and Fig. 3) . Both statins and fibrates significantly decreased VLDL-apo C-Ⅲ levels in patients with dyslipidemia by reducing the production and increasing the fractional catabolic rate of VLDL-apo C-Ⅲ 28, 29) . The apo B-48/TG ratio was the only index that could distinguish patients with type Ⅲ HL from those with other types of HL after the initiation of lipidlowering interventions (Table 1 and 3) . Fibrates strongly decrease TG levels in patients with accumulated TG-rich lipoproteins by increasing LPL activity; however, they only minimize the size of remnant lipoproteins and cannot improve hepatic uptake of these remnants because of the genetic dysfunction of apo E2/E2. We estimated that the apo B48/TG ratio yields an AUC-ROC value of 0.895 (Fig. 2) , which indicates that the ratio has a high accuracy rate in detecting type Ⅲ HL (cut-off value, 0.110; error rate vs. type Ⅲ HL, 2.8%). Using an automated chemical analyzer in our CLEIA system (the results are available within 2 h), the apo B-48/TG ratio will provide a simple index for screening type Ⅲ HL before as well as after the administration of lipid-lowering agents.
Atherogenicity of Type Ⅲ HL after Lipid-Lowering Intervention
Emerging evidence has shown that CM remnants might be responsible for the initiation and development of atherosclerotic plaques in vitro and in vivo 2) . High fasting apo B-48 is correlated with premature carotid artery stenosis 21, 22) and the existence of CHD among other metabolic biomarkers related to coronary risk, and the combination with other impaired biomarkers represents a stronger risk state for CHD (Masuda D et al., unpublished observation, 2011) . Many in vitro and in vivo studies have shown that small CM remnants may play an important role in the initiation and development of atherosclerotic plaques 2) . The size of CMs and CM remnant particles produced from the intestine during the postprandial period has varied from a large CM to small LDL or HDL 2, 30) . A high apo B-48/TG ratio indicates the accumulation of small CM remnants that contain one apo B-48 molecule and lower TG content than in large CM particles.
Clinical Indices for Screening Type Ⅲ HL after Lipid-Lowering Interventions
Five groups of investigators have developed and evaluated clinical indices for screening type Ⅲ HL before the initiation of lipid-lowering interventions [12] [13] [14] [15] [16] . We evaluated whether their clinical indices including the apoB-48/TG ratio were also useful for screening type Ⅲ HL when lipid and lipoprotein profiles were already improved by lipid-lowering agents ( Table 3 and Fig. 3) . A high apo E/apo B ratio was based on the concept that the accumulation of remnant lipoproteins increases apo E but not apo B levels 12) ; fibrates reduce apo B levels in patients with type Ⅰ HL resulting in a high apo E/apo B ratio in patients with type Ⅰ HL as well as type Ⅲ HL. A low apo B/ TC ratio 13) was based on the concept that remnant lipoproteins are larger and contain more lipids than LDL particles; this increases serum cholesterol levels and decreases apo B levels. Since statins and fibrates effectively decrease both TC and apo B levels, low apo B/TC levels are observed in patients with type Ⅰ HL as well as type Ⅲ HL ( Table 1) . In an algorithm by Sniderman et al., a high TC/apo B ratio discriminated patients with type Ⅰ, Ⅲ, and Ⅴ HL, and a low TG/ apo B ratio discriminated patients with type Ⅲ HL among them 14) . This might be based on the concept that the accumulation of remnant lipoproteins results in greater cholesterol content than that of LDL but a lower TG content than that of CM or VLDL. Statins and fibrates effectively decrease both TC and apo B levels, high TC/apo B levels were also observed in patients with type Ⅰ as well as type Ⅲ HL and the TG/ apo B ratio was significantly lower in patients with type Ⅲ HL than in those with type Ⅰ HL ( Table 1) . This algorithm may be useful even after the administration of lipid-lowering agents; however, the cut-off value that divided type Ⅰ or Ⅲ HL from the other types of HL was lower than that of the TC/apo B ratio reported by Sniderman et al. (TC/apo B ＞6.2) 14) . The non-HDL-C/apo B ratio relates to the cholesterol content in one particle of remnant lipoproteins and LDL, and a high non-HDL-C/apo B ratio indicates the accumulation of remnant lipoprotein and LDL 15) . Statins and fibrates decrease the cholesterol content of remnant lipoproteins in patients with type Ⅲ HL, and the non-HDL-C/apo B ratio was significantly highest in patients with not only type Ⅲ HL but also type Ⅰ HL (Table 3 and Fig. 3) . The high non-HDL-C/apo B ratio in patients with type Ⅰ HL may be caused by impaired LPL activity, which could not decrease CM and CM remnants even after lipid-lowering intervention with fibrates. A high apo E/apo C-Ⅲ ratio was based on the lipoprotein profile in which apo E levels In patients with type Ⅲ HL, the apo E2/E2 phenotype may continuously prevent the liver uptake of small CM remnants, resulting in the accumulation of small CM remnants, and lipid-lowering drugs do not improve this uptake. High fasting apo B-48 and the accumulation of small CM remnants should be treated carefully and reduced using a variety of nutritional and pharmacological approaches. It was reported that atorvastatin markedly improved the postprandial increase in apo B-48-containing lipoproteins in patients with type Ⅲ HL 1) . The apo B-48/TG ratio remained high in patients with type Ⅲ HL in the current study despite appropriate lipid-lowering treatment with fibrates or statins ( Table 1 , 2, and 3), which implied that fibrate and statin therapies could not decrease small CM remnants that are clearly atherogenic. For a sufficient decrease in CMs and CM remnants in patients with type Ⅲ HL, the intestinal production of CM must be suppressed along with the increase in LPL activity. In our recent study, we reported that an intestinal cholesterol transporter inhibitor, ezetimibe, improves postprandial HL in patients with type Ⅱb HL 30) , possibly due to a reduction in intestinal cholesterol uptake and the formation of apoB-48 and CMs 31) . Combination therapy with fibrates and ezetimibe may more effectively decrease CMs and small CM remnants and may prevent the development of atherosclerotic plaques in patients with type Ⅲ HL.
Limitation of the Study
The present study was performed with a small number of patients with type Ⅲ HL (n = 12) because it is a very rare familial disorder. It may be necessary to examine whether the apo B-48/TG ratio is useful for detecting type Ⅲ HL with a large-scale study.
Conclusion
In conclusion, these data suggest that the apo B-48/TG ratio is a novel and useful marker for detecting type Ⅲ HL, even after the initiation of lipid-lowering therapy.
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